ArticleBioinformatics (Oxford, England)2026
One-hot news: drug synergy models shortcut molecular features.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DeepSynBa: actionable drug combination prediction with complete dose-response profiles.Bioinformatics (Oxford, England) · 2026Article
- Cosynllm: predicting drug combination synergy with LLM-generated descriptions.Journal of cheminformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
motivationCombinatorial drug therapy holds great promise for tackling complex diseases, but the vast number of possible drug combinations makes exhaustive experimental testing infeasible. Computational models have been developed to guide experimental screens by assigning synergy scores to drug pair-cell line combinations, where they take input structural and chemical information on drugs and molecular features of cell lines. The premise of these models is that they leverage this biological and chemical information to predict synergy measurements.
resultsIn this study, we demonstrate that replacing drug and cell line representations with simple one-hot encodings results in comparable or even slightly improved performance across diverse published drug combination models. This unexpected finding suggests that current models use these representations primarily as identifiers and exploit covariation in the synergy labels. Our synthetic data experiments show that models can learn from the true features; however, when drugs and cell lines recur across drug-drug-cell triplets, this repeating structure impairs feature-based learning. While the current synergy prediction models can aid in prioritizing drug pairs within a panel of tested drugs and cell lines, our results highlight the need for better strategies to learn from intended features and to generalize to unseen drugs and cell lines. AVAILABILITY AND IMPLEMENTATION: The scripts to run the experiments are available at: https://github.com/tastanlab/ohe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.